Aldeyra Therapeutics, Inc. (ALDX) — Current Report

AI-Powered SEC Filing Analysis

Latest Current Report Filed: 2026-05-01

Key Insights

Aldeyra disclosed treatment efficacy estimates and confidence intervals for reproxalap's primary endpoints across all proposed commercial dosing regimens for dry eye disease, suggesting the company is advancing toward NDA review with specific clinical data ready for FDA evaluation.
The filing reveals Aldeyra's interpretation of FDA positions on primary endpoints alongside company positions, indicating potential disagreement with regulators that could impact approval timelines or labeling claims for reproxalap.
This Regulation FD disclosure of a corporate overview presentation appears designed to provide investor transparency on clinical trial data and regulatory strategy, though the cautionary language suggests management is being careful about forward-looking statements.

Want the newest filings?

This analysis covers the filing from 2026-05-01. New 10-K, 10-Q and 8-K filings are analyzed the moment they are released — exclusively in the app.

Download on the App Store Open in app →

Earlier Current Report filings

Filed: 2026-04-01

Aldeyra Therapeutics has paid off the outstanding $15 million borrowings and terminated the Hercules Credit Facility, indicating improved financial position.
The company's cash, cash equivalents, and marketable securities as of December 31, 2025 are expected to support operations into 2028, providing a solid financial runway.
The termination of the Hercules Credit Facility suggests Aldeyra may be exploring alternative financing options or has secured sufficient funding to advance its pipeline and operations.

Filed: 2025-12-31

Dr. Stephen G. Machatha, the Chief Development Officer, has decided to voluntarily resign from his position to pursue other professional opportunities.
The company has entered into a Transition Agreement with Dr. Machatha, which will allow for a smooth transition of his duties and responsibilities until his last day of employment on or before March 31, 2026.
Dr. Machatha will continue to receive his base salary and have his outstanding equity awards continue to vest during the Transition Period, and he will also be entitled to a lump-sum payment of $88,000 representing a portion of his potential 2025 bonus.

Other reports for Aldeyra Therapeutics, Inc.

Insider Trading

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.